文献速递瓣膜外科先天性心脏病外科

对称性二叶化修复用于先天性主动脉瓣或干瓣疾病患者

Symmetric bicuspidizing repair for patients with congenital aortic or truncal valve disease.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-10-15

该回顾性研究纳入波士顿儿童医院2019年12月至2022年6月接受对称性二叶化修复的23例患者,与接受其他二叶化手术的18例患者对比。对称性二叶化修复组术后21个月免于中度主动脉瓣反流为87.5%,高于其他二叶化组的43.5%(P = .03);免于瓣膜相关再手术为100%,高于其他组的64.4%(P = .02)。作者认为该技术可安全扩展用于多种先天性主动脉瓣和干瓣疾病。

要点

  • 对称性二叶化修复组术后21个月免于中度主动脉瓣反流87.5%,其他二叶化组43.5%(P = .03)。
  • 对称性二叶化修复组免于瓣膜相关再手术100%,其他二叶化组64.4%(P = .02)。
  • 全队列手术死亡1例(2.4%),晚期死亡1例。

核心结论

  • 对称性二叶化修复可安全扩展用于多种形式的先天性主动脉瓣和干瓣疾病患者。
  • 需要更长期随访以确定该技术与新瓣叶化及Ross手术的比较有效性。

研究设计与样本

  • 回顾性研究,纳入波士顿儿童医院2019年12月至2022年6月接受对称性二叶化修复的患者23例,并以同期接受其他形式二叶化手术的患者18例作为对照。
  • 评估指标包括生存、瓣膜相关再手术以及中度或以上主动脉瓣或干瓣反流的发生。

主要发现

  • 术前存在主动脉瓣反流者占87.0%。
  • 对称性二叶化修复组更常接受缝线瓣环成形术(100% vs 55.6%;P = .002)和升主动脉成形术(78.3% vs 27.8%;P = .004)。
  • 全队列手术死亡1例(2.4%),晚期死亡1例。
  • 对称性二叶化修复组术后21个月免于中度主动脉瓣反流为87.5%,其他二叶化组为43.5%(P = .03)。
  • 对称性二叶化修复组免于瓣膜相关再手术为100%,其他二叶化组为64.4%(P = .02)。

局限性

  • 需要更长期随访以确定该技术与新瓣叶化及Ross手术的比较有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Symmetric bicuspidizing repair has been shown to be safe and effective in the short term in adults and children with unicuspid aortic valve. Outcomes of extending this technique to patients with other forms of aortic and truncal valve disease have not been reported. METHODS: We performed a retrospective review of patients who underwent the symmetric bicuspidizing repair at Boston Children's Hospital between December 2019 and June 2022 with a contemporary comparator group of patients who underwent other forms of bicuspidization. Survival, valve-related reoperation, and the development of moderate or greater aortic or truncal valve regurgitation were assessed. RESULTS: There were 23 patients who underwent symmetric bicuspidizing repair and 18 who underwent another form of bicuspidization. Preoperative aortic regurgitation was present in 87.0%. Patients who underwent symmetric bicuspidizing repair more commonly underwent suture annuloplasty (100% vs 55.6%; P = .002) and ascending aortoplasty (78.3% vs 27.8%; P = .004). There was 1 operative mortality (2.4%) in the entire cohort and 1 late mortality. Freedom from moderate aortic regurgitation was 87.5% at 21 months after symmetric bicuspidizing repair compared with 43.5% for patients who underwent other types of bicuspidization; P = .03. Freedom from valve-related reoperation was 100% in the symmetric bicuspidizing repair group compared with 64.4%; P = .02. CONCLUSIONS: The symmetric bicuspidizing repair may be safely extended to patients with various forms of congenital aortic and truncal valve disease. Longer term follow-up will be necessary to determine the comparative effectiveness of this technique compared with neocuspidization and the Ross procedure.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chiu P, Chávez M, Zubair MM, et al. Symmetric bicuspidizing repair for patients with congenital aortic or truncal valve disease. J Thorac Cardiovasc Surg. 2022. PMID: 36369158. doi:10.1016/j.jtcvs.2022.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。